Citrate Pharmacokinetics and Regional Citrate Anticoagulation in CRRT
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00948558|
Recruitment Status : Unknown
Verified August 2009 by Huashan Hospital.
Recruitment status was: Recruiting
First Posted : July 29, 2009
Last Update Posted : August 6, 2009
- To compare the differences of citrate pharmacokinetics in healthy individuals and critically ill patients as well as the influential factors.
- To validate a pharmacokinetic model which has been established in a formal paper.
- To create a safe and effective RCA-CRRT protocol.
|Condition or disease|
|Acute Kidney Failure With or Without: MODS Sepsis Hepatic Insufficiency|
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Observational Model:||Case Control|
|Official Title:||Citrate Pharmacokinetics in Healthy Individuals and Critically Ill Patients and the Application of Regional Citrate Anticoagulation in Continuous Renal Replacement Therapy(RCA-CRRT).|
|Study Start Date :||March 2009|
|Estimated Primary Completion Date :||December 2010|
|Estimated Study Completion Date :||September 2011|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00948558
|Contact: Feng Ding, Professoremail@example.com|
|Shanghai, China, 200040|
|Contact: Feng Ding, doctor 81-02152888135 firstname.lastname@example.org|